Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Penthrox is launched in Italy

Oct 23, 2019Mark EdwardsNews

23 October 2019

ASX Announcement

Penthrox® is launched in Italy

Medical Developments International Ltd (ASX: MVP) is delighted to announce that Penthrox has been launched in Italy.

MVP CEO Mr. John Sharman said, “We are delighted to finally launch Penthrox in the important European market of Italy.  There has been a number of clinical studies completed in preparation for the launch of Penthrox in Italy.  In particular, a study of 272 trauma patients in 15 Italian emergency units (MEDITA), showed that Penthrox was SUPERIOR to Standard of Care, including Opioids, for adult trauma pain patients in Italy.”

For further details, please click on the following link – Penthrox is launched in Italy

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter